PMID-sentid Pub_year Sent_text comp_official_name comp_offsetprotein_name organism prot_offset 12145682-4 2002 Our data showed a protective effect from prednisone poor response in patients with the IL-10 G/G genotype, whereas no association of the risk of relapse and IL-10 genotype was found. Prednisone 41-51 interleukin 10 Homo sapiens 87-92 15598322-10 2004 For the IL-10 groups, two of 15 patients with the high producer genotype (13.3%) remained on prednisone, in comparison with 16 of 28 patients with the intermediate producer genotype (57.1%) and 15 of 26 patients with the low producer genotype (57.7%, p = 0.01). Prednisone 93-103 interleukin 10 Homo sapiens 8-13 12145682-0 2002 Association of initial response to prednisone treatment in childhood acute lymphoblastic leukaemia and polymorphisms within the tumour necrosis factor and the interleukin-10 genes. Prednisone 35-45 interleukin 10 Homo sapiens 159-173 22447883-9 2012 CONCLUSION: The present study provides the first evidence of increased CD25(-)FOXP3(+) cells in RA patients, which were associated with disease activity and with GC treatment in carriers of the high IL-10 genotype, suggesting that this population plays a role in the clinical response to prednisone in RA. Prednisone 288-298 interleukin 10 Homo sapiens 199-204 35043219-5 2022 Importantly, the levels of salivary IL-6, IL-10, IFN-gamma, and TNF-alpha in RAS patients were significantly decreased following prednisone treatment (all P < 0.001). Prednisone 129-139 interleukin 10 Homo sapiens 42-47 29254235-6 2017 After treatment with prednisone alone, proportions of Th17/CD4+ cells and levels of IL-17A were significantly lower than in control cells, and proportions of Treg/CD4+ cells and levels of IL-10 significantly higher than in controls (all P < 0.01). Prednisone 21-31 interleukin 10 Homo sapiens 188-193 29254235-7 2017 Our results suggest that prednisone may improve pregnancy outcomes by restoring immunological homeostasis through up-regulation of STAT5 and FOXP3, induction of DIC differentiation into Treg cells, inhibition of DIC differentiation into Th17 cells, reduction of IL-17A secretion and induction of IL-10 secretion. Prednisone 25-35 interleukin 10 Homo sapiens 296-301 25611207-7 2015 A significant increment in IL-10 and a significant decrement in IL-6 (p<0.05) were also observed with prednisone both at rest and during exercise, without significant change in IL-1beta. Prednisone 105-115 interleukin 10 Homo sapiens 27-32 28154512-11 2016 In the additive genetic model results for each IL10 polymorphism, the rs1800871 and rs1800872 polymorphisms represented a marginal association with OS (p = 0.09 and p = 0.06) and PFS (p = 0.05 and p = 0.08) in B-cell lymphoma patients treated with rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP). Prednisone 311-321 interleukin 10 Homo sapiens 47-51 23968502-6 2013 Treatment with the anti-SLE therapy, particularly with prednisone, leflunomide and methotrexate, significantly improved the imbalance of these types of FoxP3(+) T cells and increased the concentrations of serum IL-10 in the drug-responding patients. Prednisone 55-65 interleukin 10 Homo sapiens 211-216 19199277-10 2009 Patients receiving high dose prednisone produced higher IL10, but they also were the patients with a more active disease. Prednisone 29-39 interleukin 10 Homo sapiens 56-60 20952465-10 2010 The antiinflammatory balance observed in high IL-10/low TNF-alpha patients treated with prednisone supports the use of these genetic polymorphisms as predictors of response to corticosteroid therapy. Prednisone 88-98 interleukin 10 Homo sapiens 46-51 20080912-6 2010 Evaluation of clinical response to treatments indicated that carriage of the high IL-10 genotype was associated with a favorable outcome (p = 0.009), specifically to prednisone therapy (p = 0.0003). Prednisone 166-176 interleukin 10 Homo sapiens 82-87 20080912-8 2010 CONCLUSION: Results show an association between the low IL-10 producer genotype and protection from RA; nevertheless, when other specific genetic and/or environmental factors trigger onset of RA, this genotype may predispose to development of anti-CCP+ RA disease with reduced response to prednisone treatment. Prednisone 289-299 interleukin 10 Homo sapiens 56-61 17086913-4 2006 Combined therapy with Avonex, prednisone and AZA was associated with a significant increase in the serum level of interleukin (IL)10 (P <0.001). Prednisone 30-40 interleukin 10 Homo sapiens 114-132